P. P. Sfikakis, MD; P. H. Kaklamanis, MD; A. Elezoglou, MD; N. Katsilambros, MD; P. G. Theodossiadis, MD; S. Papaefthimiou, MD; N. Markomichelakis, MD
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, et al. Infliximab for Recurrent, Sight-Threatening Ocular Inflammation in Adamantiades–Behçet Disease. Ann Intern Med. 2004;140:404-406. doi: 10.7326/0003-4819-140-5-200403020-00025
Download citation file:
Published: Ann Intern Med. 2004;140(5):404-406.
TO THE EDITOR:
Background: In Adamantiades–Behçet disease, recurrent ocular inflammation may lead to loss of vision despite continuous immunosuppressive therapy (1-3). Preliminary evidence suggests that the anti–tumor necrosis factor (TNF) monoclonal antibody infliximab rapidly controls sight-threatening inflammation, a critical factor in avoiding chronic, irreversible retinal lesions (4, 5).
Objective: In this open, prospective study, we report on 25 patients who were treated with a single infliximab infusion at the immediate onset of a relapse. The primary outcome measure was the time to complete suppression of ocular inflammation. We also report on 15 of these patients who had experienced at least one additional relapse while taking immunosuppressive therapy in the 32-week period before infliximab administration. These patients were enrolled in a subsequent 32-week protocol of continuous infliximab therapy. The primary outcome measures were a possible decrease in the frequency of relapses and final visual acuity.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only